Evidence map›Paper›PMID 39980074›Full record

SynthesisBMC pharmacology & toxicology2025

Aspirin plus clopidogrel versus cilostazol -based triple antiplatelet therapy in patients with ischemic heart disease undergoing PCI: a systematic review and meta-analysis of randomized controlled trials.

Ramez M Odat, Mushood Ahmed, Sakhr Alshwayyat, Ayham Mohammad Hussein, Taif Haitham AlSaraireh, Ahmad M Molhem, Ali O Aldamen, Malak Ababneh, Bishr Quwaider, Hritvik Jain and 3 more

Erratum issuedAbstract readSystematic ReviewMeta-AnalysisComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Ramez M OdatFaculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.ORCID 0009-0008-3423-4055
Mushood AhmedRawalpindi Medical University, Rawalpindi, Pakistan.
Sakhr AlshwayyatKing Hussein Cancer Center, Amman, Jordan.
Ayham Mohammad HusseinFaculty of Medicine, Al-Balqa' Applied University, Salt, Jordan.ORCID 0009-0006-3277-1549
Taif Haitham AlSarairehMinistry of Health, Amman, Jordan.ORCID 0000-0002-7467-9613
Ahmad M MolhemFaculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.ORCID 0009-0001-0470-449X
Ali O AldamenFaculty of Medicine, Al Yarmouk University, Irbid, Jordan.ORCID 0009-0007-8939-9300
Malak AbabnehFaculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.ORCID 0009-0007-8325-8291
Bishr QuwaiderFaculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.ORCID 0009-0005-4319-0814
Hritvik JainDepartment of Internal Medicine, All India Institute of Medical Sciences (AIIMS), Jodhpur, India.ORCID 0000-0001-5608-4299
Jehad A YasinSchool of Medicine, The University of Jordan, Amman, Jordan.ORCID 0000-0002-9205-2988
Hamdah HanifaFaculty of Medicine, University of Kalamoon, Al-Nabk, Syria. hamdahhanifa@gmail.com.ORCID 0000-0003-2970-7379
Raheel AhmedDepartment of Cardiology, National Heart and Lung Institute, Imperial College London, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCilostazol has been widely used to prevent peripheral vascular events after PCI. However, guidelines in cilostazol-based triple antiplatelet therapy for patients with ischemic heart disease undergoing PCI remain unclear. The purpose of this study was to assess the efficacy and safety of DAPT (aspirin and clopidogrel) compared to cilostazol -based TAPT (aspirin, clopidogrel and cilostazol).

methodsWe conducted a comprehensive search of the Medline, Embase, Scopus, Cochrane, and Web of Science databases until November 2024 to identify RCTs comparing DAPT with cilostazol -based TAPT in patients with ischemic heart disease undergoing PCI. Pooled risk ratios (RRs) with 95% CIs were calculated.

resultsEight RCTs (5,299 patients) were included in this systematic review and meta-analysis. A significantly reduced risk of all-cause mortality in hospital was observed with DAPT compared to cilostazol -based TAPT (RR: 0.27, 95% CI: 0.07 to 0.94, p = 0.04). Also, A significantly reduced risk of headache and palpitation was observed with DAPT compared to cilostazol -based TAPT, with pooled RR (RR: 0.15, 95% CI: 0.06 to 0.33, p < 0.001) and (RR: 0.24, 95% CI: 0.08 to 0.73, p = 0.01), respectively. However, no difference was observed between DAPT and cilostazol -based TAPT on vessel revascularization, stroke, stent thrombosis, myocardial infarction and major adverse cardiac events.

conclusionAspirin and clopidogrel were associated with a lower risk of adverse events compared to cilostazol-based TAPT. However, the addition of cilostazol did not improve clinical outcomes. Further trials are needed to clarify the role of cilostazol -based TAPT for patients with ischemic heart disease undergoing PCI.

Indexed as

AspirinCilostazolClopidogrelMyocardial IschemiaPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsDrug Therapy, CombinationHumansRandomized Controlled Trials as TopicAspirinCilostazolClopidogrelPlatelet Aggregation InhibitorsCilostazolDAPTHeartPCITAPT

Identifiers

PMID39980074
PMCPMC11841151

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.